Chugai Pharmaceutical Co.

From Wikipedia, the free encyclopedia
  (Redirected from Chugai Pharmaceuticals)
Jump to: navigation, search
Chugai Pharmaceutical Co., Ltd.
Type Incorporation
Headquarters

Nihonbashi Mitsui Tower, Nihonbashi Muromachi 2-1-1, Chūō, Tokyo

On the registration Headquarter: Tokyo Kita (Tokyo)
Website [1]

Chugai Pharmaceutical Co., Ltd. (中外製薬株式会社 Chūgai Seiyaku Kabushikigaisha?) is a subsidiary drug manufacturer operating in Japan controlled by Hoffmann–La Roche, which owns 62% of the company as of June 30, 2014.[1] Previous to Roche's takeover in 2002, Chugai was a pioneering discoverer of many important pharmaceutical compounds. Osamu Nagayama is the current representative director, chairman, and CEO and Tatsuro Kosaka is the current representative director, president, and COO.

History[edit]

Other notable developments[edit]

Scientists at Chugai discovered an erythromycin-derived motilin agonist called Mitemcinal (aka GM-611 or 3'-N-dimethyl-11-deoxy-3'-N-isopropyl-12-O-methyl-11-oxo-8,9-didehydroerythromycin.) Mitemcinal was believed to have strong prokinetic properties, similar to its parent molecule, but lack antibiotic properties. Presently, erythromycin is commonly used off-label for gastric motility indications such as Gastroparesis. If Mitemcinal can be shown to be as effective a prokinetic agent, it would represent a significant advance in the GI field as treatment with this drug would not carry the risk of unintentional selection of antibiotic-resistant bacteria.

External links[edit]

  • Chugai Pharmaceutical Co., Ltd. [2]
  • The transfer of operations of the Company [2]

References[edit]